Post menopausal hormone therapy today

Ethnicity and Disease

Volumn 15, Issue 2 SUPPL. 2, 2005, Pages

  Rice, Valerie Montgomery ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

HRT; Menopause; Quality of life; Vasomotor symptoms

Indexed keywords

ADRENERGIC SYSTEM; ATROPHY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; UROGENITAL SYSTEM; UTILIZATION REVIEW; WOMEN'S HEALTH;

ATROPHY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; UROGENITAL SYSTEM; VASOMOTOR SYSTEM; WOMEN'S HEALTH;

EID: 61849104128     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Dennerstein 1, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96: 351-358.
2. McKinlay SM, Brambilla DJ, Posner JG. The normal menopausal transition. Maturitas. 1992;14:103-115.
3. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-facial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152:463-473.
4. Rannevik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG, and bone mineral density. Maturitas. 1995;21:103-113.
5. Notelovitz M, Lenihan JP, McDetmott M, et al. Initial 17 beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000; 95:726-731.
6. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982-988.
7. Wiklund I, Berg G, Hammar M, et al. Long-term effect of ttansdetmal hotmonal therapy on aspects of quality of life in postmenopausal women. Maturitas. 1992;14:225-236.
8. Elia D, Tambotini A, Leomach Y, et al. Efficacy and tolerability of low dose of Oesclim (25 meg daily) in the management of symptomatic menopausal women: a French open-label study. Curr Med Res Opin. 2000; 16:94-106.
9. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001 ;75:1065-1079.
10. MacLaren A, Woods NF. Midlife women making hormone therapy decisions. Womens Health Issues. 2001;11:216-230.
11. Wilhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21:464-480.
12. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand. 1997;76:442-448.
13. Bachmann GA, Leiblum SR, Kemmann E, et al. Sexual expression and its determinants in the post-menopausal woman. Maturitas. 1984;8:19-29.
14. Semmens JP, Tsai CC, Semmens EC, et al. Effects of estrogen thetapy on vaginal physiology during menopause. Obstet Gynecol. 1985;66:15-18.
15. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-544.
16. Sarrel PM. Effects of hormone replacement thetapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med. 2000;9:S25-S32.
17. Sarrel PM. Sexuality and menopause. Obstet Gynecol. 1990;75:26S-30S.
18. Nathorst-Boos J, Wiklund I, Mattsson LA, et al. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet Gynecol Scand. 1993:72:656-660.
19. Raz R, Stamm WE. A controlled trial of inttavaginal esttiol in postmenopausal women with recurtent urinary ttact infections. N Engl J Med. 1993:329(11):753-756.
20. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999; 180:1072-1079.
21. Utinary incontinence in adults. NIH Consensus Statement Online. Octobet 3-5, 1988; 7(5):l-32. Available at: http://consensus.nih.gov/cons/071/071- statement.htm#l.What-IsAccessed March 10, 2003.
22. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a metaanalysis. First teport of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994;83:12-18.
23. Domm JA, Parker EE, Reed GW, et al. Factors affecting access to menopause information. Menopause. 2000;7:62-67.
24. Oldenhave A, Jaszmann LJ, Haspels AA, Everaetd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993; 168: 772-780.
25. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy-a placebo-conttolled study. Int ] Fertil Menopausal Stud. 1995;40:73-78.
26. Wiklund I, Katlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdetmal esttadiol therapy: a double-blind placebo-conttolled study. Am J Obstet Gynecol. 1993;168:824-830.
27. Tosteson AN, Gabtiel SE, Kneeland TS, et al. Has the impact of hormone replacement thetapy on health-related quality of life been undervalued? J Womens Health Gend Based Med. 2000;9:119-130.
28. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and deptessive symptoms in postmenopausal women after receiving hormone thetapy. Results from the Heart and Esttogen/Ptogestin Replacement Study (HERS) trial. JAMA. 2002;287:591-597.
29. Hays J, Ockene JK, Brunner RI., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003:348. (Early release article. Available at: http://content.nejm.otg/. Accessed March 18, 2002.
30. The North American Menopause Society. Amended repott from the NAMS Advisory Panel on Postmenopausal Hotmone Therapy. Menopause. 2003;10:6-12.
31. Bech P, Munk-Jensen N, Obel EB, et al. Combined versus sequential hotmonal replacement thetapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. Psychother Psychosom. 1998; 67:259-265.